Rahul Khara Sells 851 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 851 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $75.00, for a total transaction of $63,825.00. Following the completion of the sale, the insider directly owned 52,173 shares of the company’s stock, valued at $3,912,975. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Rahul Khara also recently made the following trade(s):

• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total transaction of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Price Performance

Shares of IRON stock opened at $74.95 on Thursday. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50. The firm has a fifty day moving average of $69.08 and a 200-day moving average of $70.50. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -11.32 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, equities research analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of large investors have recently bought and sold shares of IRON. JPMorgan Chase & Co. grew its stake in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after acquiring an additional 828,248 shares in the last quarter. BVF Inc. IL acquired a new position in Disc Medicine during the fourth quarter worth $51,616,000. Jennison Associates LLC acquired a new position in Disc Medicine during the fourth quarter worth $42,252,000. Perceptive Advisors LLC bought a new position in Disc Medicine in the fourth quarter valued at $35,794,000. Finally, RA Capital Management L.P. grew its position in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on IRON. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Morgan Stanley raised their target price on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.